Carcinoembryonic antigen in carcinoma of the uterine cervix 2. Tissue localization and correlation with plasma antigen concentration
β Scribed by J. R. Van Nagell Jr.; E. S. Donaldson; E. C. Gay; S. Hudson; R. M. Sharkey; F. J. Primus; D. F. Powell; D. M. Goldenberg
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 396 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Immunoperoxidase staining for carcinoembryonic antigen (CEA) was performed on the tumors of 241 patients with invasive carcinoma of the cervix. Positive tissue staining indicative of a CEA concentration of at least 3 pg/gm was present in 154 tumors (63%) as opposed to 0 of 30 specimens of normal cervix (p < .001). Plasma CEA values were obtained at the time of tissue staining on all patients. Plasma CEA concentration was related more directly to total tumor burden (tumor CEA content X extent of disease) than to tumor CEA concentration alone. Progressively rising plasma CEA levels predicted recurrent disease in over 80% of patients whose tumors stained positively for CEA. In contrast, serial plasma CEA values correlated positively with clinical disease status in only 28% of patients whose tumors were devoid of CEA. Immunoperoxidase staining of tissue specimens identifies those patients whose tumors contain high levels of CEA and who therefore should benefit most from subsequent plasma antigen determinations.
Cancer 44:944-948, 1979.
π SIMILAR VOLUMES
Our aim was to evaluate the clinical usefulness of serum concentrations of squamous-cell carcinoma antigen (SCC-Ag) and tissue polypeptide antigen (TPA) in the follow-up of patients with vulvar cancer. We measured SCC-Ag and TPA in 480 serum samples of 82 patients with squamous-cell vulvar cancer. R
## BACKGROUND. Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for medullary thyroid carcinoma (MTC). This Phase I/II study was initiated to determine the safety, maximum tolerated dose (MTD), and therapeutic potential of 131 I-MN-14 F(ab